Abstract:Hypertrophic scar is an important clinical problem with limited therapeutic options. Aside from their roles as 3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase inhibitors, statins have also been demonstrated to decrease scarring by reducing connective tissue growth factor (CTGF) expression. However, poor penetrative ability limits their utility as topical treatments for hypertrophic scar. Here, we aim to develop novel statin formulations using liposomes to enhance dermal penetrative ability and to evaluate their efficacy against formation of hypertrophic scar utilizing our validated rabbit ear hypertrophic scar model. Liposomal simvastatin or pravastatin were compounded using a novel, flexible liposomal formulation and applied topically to rabbit ear hypertrophic scars daily from postoperation day (POD) 14 until POD 25. Scar color, including erythema and melanin, was measured using reflectance spectrophotometry on POD 28, and scar tissue was harvested for evaluation of scar elevation index as well as gene and protein expression. Human foreskin fibroblasts were also treated with statin formulations and CCN2 expression was determined by quantitative PCR. Both simvastatin and pravastatin were efficiently encapsulated in liposomes, forming nanometer‐scale particles possessing highly negative charges. Topical treatment with liposomal simvastatin and pravastatin at 6.5% concentration significantly reduced scar elevation index and decreased type I/III collagen content and myofibroblast persistence in the wound. The erythema/vascularity of scars was reduced by liposomal statin treatment, with concomitant decrease of CD31 expression as measured histologically. Expression levels of transcripts encoding CTGF, collagen I, and collagen III collagen in scar tissue were also decreased by liposomal pravastatin treatment, as were myofibroblast persistence and the type I/III collagen ratio as assessed by immunofluorescence and picrosirus red staining, respectively. Treatment of human foreskin fibroblasts with simvastatin or with liposome‐encapsulated pravastatin resulted in decreased expression of transcript encoding CTGF. Overall, our novel statin formulations encapsulated in liposomes were successfully delivered through topical application, significantly reducing hypertrophic scarring in a rabbit ear model.

670 Topical Treatment for Abnormal Scars Using Spherical Nucleic Acids

Attenuation of Abnormal Scarring Using Spherical Nucleic Acids Targeting Transforming Growth Factor Beta 1.

Abnormal Scar Identification with Spherical-Nucleic-acid Technology

1063 Topically Applied NanoFlares to Measure Gene Expression in Vivo: Proof-of-concept

Comprehensive Modular Analyses of Scar Subtypes Illuminate Underlying Molecular Mechanisms and Potential Therapeutic Targets.

Endogenous stimuli-responsive separating microneedles to inhibit hypertrophic scar through remodeling the pathological microenvironment

Advances of Nanobiomaterials for Treating Skin Pathological Fibrosis

Liposome‐encapsulated statins reduce hypertrophic scarring through topical application

Transdermal delivery of Chinese herbal medicine extract using dissolvable microneedles for hypertrophic scar treatment

New challenges in scar therapy: the novel scar therapy strategies based on nanotechnology

MiR-141-3p-Functionalized Exosomes Loaded in Dissolvable Microneedle Arrays for Hypertrophic Scar Treatment

Topical Delivery of Sirna-Based Spherical Nucleic Acid Nanoparticle Conjugates for Gene Regulation

ADSCC‐CM‐Induced Keratin Hydrogel‐Based Bioactive Microneedle Patch Containing Triamcinolone Acetonide for the Treatment of Pathological Scar

NIR-II light based combinatorial management of hypertrophic scar by inducing autophagy in fibroblasts

The Treatment of Keloid Scars via Modulating Heterogeneous Gelatin-Structured Composite Microneedles to Control Transdermal Dual-Drug Release

Anti-Scarring Drug Screening with Near-Infrared Molecular Probes Targeting Fibroblast Activation Protein-α.

A Review of the Effectiveness of Fluorescence Spectroscopy and Imaging for Non-Invasive Skin Cancer Diagnosis

Topical application of an irreversible small molecule inhibitor of lysyl oxidases ameliorates skin scarring and fibrosis

Combination of lyophilized adipose-derived stem cell concentrated conditioned medium and polysaccharide hydrogel in the inhibition of hypertrophic scarring

Novel topical drug delivery systems and their potential use in scars treatment

Strategy for Hypertrophic Scar Therapy: Improved Delivery of Triamcinolone Acetonide Using Mechanically Robust Tip-Concentrated Dissolving Microneedle Array.